clinical trial · NCT07577856
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
Janssen Research & Development, LLC·phase3·recruiting·n = 644
Colitis, UlcerativeJNJ-78934804Guselkumab
brief summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops ulcers).
started
May 23, 2026
primary completion
Aug 11, 2028
completion
Oct 30, 2030
last updated
Jun 8, 2026
official title
A Phase 3 Randomized, Double-blind, and Active Controlled, Multi-center Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol